Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University Health Network, Toronto
Kineta Inc.
National Cancer Institute, Naples
University College, London
Saitama Medical University International Medical Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano